ANP profits rise as premium products offset Asia weakness
Premium products and IMEA growth helped lift profits despite a decline in Asia's toxin binder. Revenue rose 7% to £24.3m, adjusted EBITDA increased 22%, and EPS rose 30%. Profit guidance remains unchanged despite a softer start in H2.